Table 2.
Demographic, clinical and paraclinical characteristics of COVID-19 patients
| Demographic Variables | No. (%)/Mean±SD |
|---|---|
| Sex (male) | 20(69) |
| Marital status (married) | 27(93.1) |
| Age (y) | 51.62±15.99 |
| Educational status (y) | 8.28±5.95 |
| Residency (city) | 21(72.4) |
| Number of family members | 3.31±2.01 |
| Ethnicity (native) | 16(55.2) |
| Jobless | 9(31) |
| History of influenza vaccine | 4(14.3) |
| Travel 14 days ago | 5(17.9) |
| Contact the people of Corona-infected cities | 2(7.1) |
| Contact a person with corona | 15(53.6) |
| Pet | 4(14.3) |
| Under lying disease (yes) | 9(31) |
| Smoking (yes) | 2(6.9) |
| Addiction (yes) | 2(6.9) |
| Duration of hospitalization | 8.07±2.4 |
| Vital Signs | |
| BP (systolic) | 118.48±14.38 |
| BP (diastolic) | 78.56±8.69 |
| Temprature | 38.22±11.31 |
| Pulse rate | 92.52±11.47 |
| Respiratory rate | 15.28±2.6 |
| Clinical Signs & Symptoms | |
| O2 sat | 92.69±2.47 |
| Fever | 18(64.3) |
| Pharyngitis | 3(10.7) |
| Dry cough | 18(64.3) |
| Dyspnea | 13(46.4) |
| Rhinorrhea | 0 |
| Chills | 17(60.7) |
| Demographic Variables | No. (%)/Mean±SD | |
|
| ||
| Vomiting | 8(28.6) | |
|
| ||
| Nausea | 6(21.4) | |
| Diarrhea | 5(17.9) | |
| Headache | 16(57.1) | |
| Myalgia | 11(39.3) | |
| Joint pain | 11(39.3) | |
| Anorexia | 6(21.4) | |
| Epistaxis | 0 | |
| Fatigue | 19(67.9) | |
| Convulsion | 0 | |
| Loss of consciousness | 0 | |
| Abdominal pain | 7(25) | |
| Radiological and Paraclinical Features | ||
| COVID-19 RT-PCR test (positive) | 29 (100) | |
| Chest CT Scan (ground-glass opacity) | 29 (100) | |
| Hematology | Result | Reference value |
| WBC×103/mm3 | 9372.57±1652.473 | 4000–10000 |
| Neutrophils (%) | 70.64±9.3 | 36–80 |
| Lymphocytes(%) | 26.24±8.68 | 16–51 |
| Eosinophils (%) | 3.03±1.12 | 0.0–6 |
| RBC×106/mm3 | 4.5±0.57 | 4.5–6.3 |
| Hb (mg/dl) | 13.46±1.79 | 14–18 |
| HCT (%) | 40.1±3.71 | 39–52 |
| PLT×103/μL | 209±72 | 140–450 |
| FBS/BS (mg/dL) | 141.36±11.28 | 90–110 |
| ESR (mm/hr) | 23.19±16.37 | Up to 15 |
| CRP (mg/dL) | 26.14±26.18 | <6 |
| PT(Sec) | 12.45±1 | 10.7–13.1 |
| PT control (sec) | 11.5 | 70–100 |
| PTT (sec) | 33.77±4.45 | 24–42 |
| INR (%) | 1.0 | 0.9–1.0 |
| Total bilirubin (mg/dL) | 0.8±0.52 | 0.2–1.2 |
| Demographic Variables | No. (%)/Mean±SD | |
|---|---|---|
| Direct Bilirubin (mg/dL) | 0.29±0.14 | 0–0.4 |
|
| ||
| BUN (mg/dL) | 37.63±14.72 | 7–21 |
| Creatinine (mg/dL) | 1.09±0.41 | 0.7–1.4 |
| AST (IU/L) | 41.5±31.8 | 0–41 |
| ALT (IU/L) | 33.16±14.04 | 0–37 |
| ALP (IU/L) | 179.43±123.33 | 64–306 |
| Serum Na+ (mEq/L) | 134.5±28.64 | 135–145 |
| Serum K+ (mEq/L) | 4.12±0.83 | 3.5–5.2 |
| Serum Ca2+ (mEq/L) | 8.68±1.57 | 8.5–10.5 |
| P (mg/dL) | 3.41±0.71 | 2.5–5 |
ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; AST: Aspartate aminotransferase; BP: Blood pressure; BS: Blood sugar; BUN: Blood urea nitrogen; Ca: Calcium; Cr: Creatinine, CRP: C-reactive Protein, COVID-19: Coronavirus 2019; ESR: Erythrocyte sedimentation rate; FBS: Fasting blood sugar; Hb: Hemoglobin; HCT: Hematocrit; K: Potassium; MRI: Magnetic resonance imaging; Na: Sodium; O2 Sat.: Oxygen saturation; PLT: Platelet; PT: Prothrombin time; PTT: Partial thromboplastin time; P: Phosphorus; RBC: Red blood cells; RT-PCR: Real-time reverse transcription polymerase chain reaction; WBC: White blood cells.